Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.
about
Mechanisms involved in the development of chemotherapy-induced neuropathyMechanisms of chemotherapy-induced behavioral toxicitiesAstrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the ratThe anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse modelInhibition of Mitochondrial p53 Accumulation by PFT-μ Prevents Cisplatin-Induced Peripheral Neuropathy.Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.Molecular imaging detects impairment in the retrograde axonal transport mechanism after radiation-induced spinal cord injury.A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapyFollow-up psychophysical studies in bortezomib-related chemoneuropathy patients.Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.Gabapentin prevents oxaliplatin-induced central sensitization in the dorsal horn neurons in ratsEvidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathyMAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4Translational approaches to treatment-induced symptoms in cancer patients.Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo modelsMinocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivityPersistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristineSubclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapyPrevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ.Minocycline attenuates bone cancer pain in rats by inhibiting NF-κB in spinal astrocytes.Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesicsPathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).The search for treatments to reduce chemotherapy-induced peripheral neuropathy.Tetracyclines and neuromuscular disorders.Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions.Neuroimmune mechanisms of behavioral alterations in a syngeneic murine model of human papilloma virus-related head and neck cancer.Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy.Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathyMatrix metalloproteinase-2 is downregulated in sciatic nerve by streptozotocin induced diabetes and/or treatment with minocycline: Implications for nerve regeneration.The Therapeutic Potential of Monocyte/Macrophage Manipulation in the Treatment of Chemotherapy-Induced Painful Neuropathy.Minocycline and fluorocitrate suppress spinal nociceptive signaling in intrathecal IL-1β-induced thermal hyperalgesic rats.Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension.Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity.Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.
P2860
Q26824380-5E62E9ED-B309-4E50-B4F2-F278CA1F0613Q26998870-287387DD-7DFB-4071-881A-3B6DB7E16F1CQ28390312-42B9FFC5-4151-4E50-9683-1DCE5DCE2B29Q28539926-7ADC8623-DEF3-4764-A897-22D498CBBA42Q33571709-5B814FB5-8100-435A-8AD3-F42E59A6E0C8Q33711666-43DC17F6-71A1-4DA6-86A3-7DCA657E2C18Q33744706-01D7149A-876F-4D00-8360-BB3C200FFAA0Q33851825-5B21AAE5-ABF1-4D33-B934-F7AB4E6386A8Q33857061-3807CA4E-0216-4289-838B-C5AD0508A202Q34438547-06B0363D-972A-4FED-83BF-0D649B893C6BQ35188312-5B02CE66-913C-423E-96FE-7254CF701668Q35740234-E5617468-4EA8-4B78-B47D-90C5EAD2B4F4Q35763462-A1CBA4B9-A378-4CED-BCAD-8B53E147BA05Q35803293-E6860E1A-90EB-443F-B4A9-63F541E79C41Q36053079-1BE85721-D712-4DB1-A3B9-A40933113E54Q36106866-DAD3D6A2-8577-44CC-87F1-BFD74A9F0F50Q36143029-7075DFC7-1EDD-4C3C-8CE3-5964AC0E88A5Q36174729-7B0F8330-CA4E-4AA0-BABC-143FB9649D91Q36179484-E2F1860A-E8D5-4848-B9AB-77E51C01DDE2Q36226275-FA1E9AD8-C5DE-4A23-AF96-3AA848581E4CQ36586687-6A7686FE-09A6-4E2E-B71F-68A98438084DQ36636831-E91ED52D-A3F3-4A97-9A5C-1297119DCD4BQ36748075-3B1F7A8E-78D9-47A9-9C39-F1DF91B538F8Q36988206-5A5D326E-D70D-4CD8-AE50-ABCBDC11EA23Q37112300-C670C9C3-DADF-40C3-9F42-F577FDB1DD9CQ37170634-DF973E56-1E86-468B-9AF2-E008919A09A5Q37399781-759C8D6F-CEDF-47FE-9923-E14D98E9E45DQ37410650-AE97B0F9-2105-4437-89AB-9B68AE87C2B5Q38064452-F07B1DB5-B17A-4732-B87F-7B47C77E1E89Q38209959-D714161C-B8C9-4050-BF88-3FF23EB0C4A1Q38929870-EF9D3EDB-310D-48F4-A158-B8C9740C0621Q41759508-0CD3F8B2-EA6D-426F-A392-B5E2B56EF355Q41943563-99B9B19C-B226-4FF5-938A-63B9716FA409Q42947312-81BEE8FB-8EAC-40BC-B300-DC0CC313DB2CQ47102190-A5ADBD67-C72D-4505-BAFC-5353794EFDF1Q48613201-089231EB-C936-4D67-BD47-77088A4417B6Q49101922-087C4F0E-C332-4EF5-94E3-02135D2299CCQ52648842-BB75B1A6-0CCD-4249-A80C-4BA5CFCA3A9DQ52693014-ACA6B679-ACB3-4925-B8A9-E2615A1C0740
P2860
Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@ast
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@en
type
label
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@ast
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@en
prefLabel
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@ast
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@en
P2860
P1476
Protection against oxaliplatin ...... rve fiber loss by minocycline.
@en
P2093
J Boyette-Davis
P M Dougherty
P2860
P304
P356
10.1016/J.EXPNEUROL.2011.02.019
P407
P577
2011-03-05T00:00:00Z